Investigating the therapeutic effects of Sotorasib on brain metastases in patients with Non-small cell lung cancer
Investigating the therapeutic effects of Sotorasib on brain metastases in patients with Non-small cell lung cancer
Mehran Ebadi,1Maryam Naderi Soorki,2,*
1. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran 2. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
Introduction: Brain metastases affect approximately 25-50% of non-small cell lung cancer (NSCLC) patients, significantly worsening prognosis and severely limiting treatment options. Sotorasib, a targeted therapy specifically developed for NSCLC with KRAS G12C mutations, has shown promising results in treating brain metastases, In this group of patients. KRAS mutations are among the most common oncogenic drivers in NSCLC, with the G12C variant being notably prevalent. Sotorasib works by irreversibly inhibiting the KRAS G12C protein, effectively blocking the signaling pathways that drive tumor growth and survival. This mechanism is particularly crucial for patients with brain metastases, where conventional therapies like chemotherapy often fail due to the blood-brain barrier.
Methods: Clinical trials, notably the CodeBreaK studies, have provided critical insights into the efficacy of sotorasib in patients with KRAS G12C-mutated NSCLC, including those with stable brain metastases. In this study, we evaluated the impact of sotorasib on the treatment of brain metastases in patients with KRAS G12C-mutated lung cancer, based on the latest research findings. Also, we explored the challenges and future prospects associated with this therapeutic approach.
Results: Studies have demonstrated that sotorasib can achieve intracranial activity, with some patients experiencing significant tumor reduction in the brain. While challenges remain, particularly in achieving complete responses in the brain, current evidence supports the continued investigation and use of sotorasib as part of a comprehensive treatment strategy for these patients.
Conclusion: Results showed the development of sotorasib can be a significant advancement, especially for treatment of brain metastases in NSCLC patients with KRAS G12C mutations, who have historically had limited therapeutic options.